We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
176
Arrowhead Research
ARWR
$11.9B
$563K 0.02%
30,700
– –
ATNX
177
DELISTED
Athenex, Inc. Common Stock
ATNX
$558K 0.02%
2,277
– –
CNCE
178
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$548K 0.02%
45,362
– –
EVH icon
179
Evolent Health
EVH
$348M
$530K 0.02%
42,150
– –
HZNP
180
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$511K 0.02%
+19,350
New +$459K
IMGN
181
DELISTED
Immunogen Inc
IMGN
$456K 0.02%
168,190
– –
DNLI icon
182
Denali Therapeutics
DNLI
$3.65B
$450K 0.02%
+19,372
New +$405K
ADYX
183
DELISTED
Adynxx Inc
ADYX
$437K 0.02%
24,750
– –
CDTX
184
DELISTED
Cidara Therapeutics
CDTX
$421K 0.02%
7,939
– –
NVAX icon
185
Novavax
NVAX
$1.2B
$315K 0.01%
28,550
– –
CAH icon
186
Cardinal Health
CAH
$53.9B
$303K 0.01%
6,300
– –
ORKA
187
Oruka Therapeutics
ORKA
$5.82B
$303K 0.01%
3,756
– –
TRIL
188
DELISTED
Trillium Therapeutics Inc.
TRIL
$294K 0.01%
446,099
– –
CLSD
189
DELISTED
Clearside Biomedical
CLSD
$228K 0.01%
11,022
– –
NUVA
190
DELISTED
NuVasive, Inc.
NUVA
$217K 0.01%
3,816
-25,000
-87% -$1.33M
BLCM
191
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$202K 0.01%
6,000
– –
JNCE
192
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$63K ﹤0.01%
10,127
– –
CLDX icon
193
Celldex Therapeutics
CLDX
$2.99B
$35K ﹤0.01%
7,053
– –
QHC
194
DELISTED
Quorum Health Corporation
QHC
$33K ﹤0.01%
23,725
– –
A icon
195
Agilent Technologies
A
$39.1B
– –
-8,200
Closed -$553K
INVA icon
196
Innoviva
INVA
$1.55B
– –
-161,603
Closed -$2.82M
LMAT icon
197
LeMaitre Vascular
LMAT
$2.32B
– –
-27,150
Closed -$642K
LXRX icon
198
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-70,000
Closed -$465K
MTD icon
199
Mettler-Toledo International
MTD
$28.6B
– –
-3,500
Closed -$1.98M
NCNA
200
NuCana
NCNA
$5.49M
– –
-2
Closed -$142K
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.